Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$16.53
-0.6%
$15.72
$12.72
$18.92
$5.94B0.58415,460 shs423,102 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$139.87
-1.6%
$128.02
$73.16
$148.11
$8.35B0.821.03 million shs1.09 million shs
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$95.96
0.0%
$99.49
$79.00
$118.01
$2.19B0.54340,268 shs317,931 shs
Liquidia Corporation stock logo
LQDA
Liquidia
$79.73
+6.1%
$58.25
$11.85
$80.69
$6.68B0.582.76 million shs1.70 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
+2.06%+11.60%+6.17%+4.93%+33.99%
Glaukos Corporation stock logo
GKOS
Glaukos
-1.56%+8.28%+37.88%+31.99%+40.06%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
+0.36%+8.34%+1.43%-12.06%+16.26%
Liquidia Corporation stock logo
LQDA
Liquidia
-3.90%-0.49%+21.58%+99.05%+473.44%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$16.53
-0.6%
$15.72
$12.72
$18.92
$5.94B0.58415,460 shs423,102 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$139.87
-1.6%
$128.02
$73.16
$148.11
$8.35B0.821.03 million shs1.09 million shs
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$95.96
0.0%
$99.49
$79.00
$118.01
$2.19B0.54340,268 shs317,931 shs
Liquidia Corporation stock logo
LQDA
Liquidia
$79.73
+6.1%
$58.25
$11.85
$80.69
$6.68B0.582.76 million shs1.70 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
+2.06%+11.60%+6.17%+4.93%+33.99%
Glaukos Corporation stock logo
GKOS
Glaukos
-1.56%+8.28%+37.88%+31.99%+40.06%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
+0.36%+8.34%+1.43%-12.06%+16.26%
Liquidia Corporation stock logo
LQDA
Liquidia
-3.90%-0.49%+21.58%+99.05%+473.44%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.21
Hold$17.928.36% Upside
Glaukos Corporation stock logo
GKOS
Glaukos
2.79
Moderate Buy$149.176.65% Upside
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
2.75
Moderate Buy$112.6017.34% Upside
Liquidia Corporation stock logo
LQDA
Liquidia
2.82
Moderate Buy$68.88-13.61% Downside

Current Analyst Ratings Breakdown

Latest LMAT, GKOS, LQDA, and BLCO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/29/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Reiterated RatingBuyNeutral$64.00 ➝ $79.00
6/22/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Boost Price TargetBuy$59.00 ➝ $109.00
6/17/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Boost Price TargetBuy$136.00 ➝ $150.00
6/11/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Boost Price TargetBuy$140.00 ➝ $162.00
6/10/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Reiterated RatingBuy$162.00
6/5/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Boost Price TargetBuy$67.00 ➝ $75.00
6/5/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Set Price Target$75.00
6/5/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Set Price Target$28.00
6/4/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Reiterated RatingStrong-Buy$68.00
6/3/2026
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Reiterated RatingOutperform$120.00
6/2/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Set Price TargetBuy$19.00
(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$5.10B1.16$1.66 per share9.97$18.40 per share0.90
Glaukos Corporation stock logo
GKOS
Glaukos
$507.44M16.19N/AN/A$11.42 per share12.25
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$249.60M8.78$2.90 per share33.08$17.35 per share5.53
Liquidia Corporation stock logo
LQDA
Liquidia
$158.32M44.79N/AN/A$0.51 per share156.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$360M-$0.6225.5815.450.51-4.21%3.60%1.69%7/29/2026 (Estimated)
Glaukos Corporation stock logo
GKOS
Glaukos
-$187.69M-$3.28N/A297.60N/A-34.34%-6.92%-5.25%7/29/2026 (Estimated)
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$57.73M$2.7137.2129.352.6724.35%15.36%9.78%8/4/2026 (Estimated)
Liquidia Corporation stock logo
LQDA
Liquidia
-$68.92M$0.14536.5716.21N/A7.74%46.82%7.06%8/11/2026 (Estimated)

Latest LMAT, GKOS, LQDA, and BLCO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Liquidia Corporation stock logo
LQDA
Liquidia
$0.4102$0.52+$0.1098$0.52$119.44 million$132.87 million
5/5/2026Q1 2026
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.66$0.68+$0.02$0.68$66.67 million$66.55 million
4/29/2026Q1 2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.06$0.08+$0.02-$0.20$1.22 billion$1.24 billion
4/29/2026Q1 2026
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.30-$0.18+$0.12-$0.34$137.00 million$150.57 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$1.001.04%+16.05%36.90%14 Years
Liquidia Corporation stock logo
LQDA
Liquidia
N/AN/AN/AN/AN/A

Latest LMAT, GKOS, LQDA, and BLCO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/28/2026
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
quarterly$0.251%5/21/20265/21/20266/4/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.78
1.53
0.99
Glaukos Corporation stock logo
GKOS
Glaukos
0.10
5.43
4.73
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
0.42
14.32
12.20
Liquidia Corporation stock logo
LQDA
Liquidia
1.18
2.22
2.03

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
84.64%
Liquidia Corporation stock logo
LQDA
Liquidia
64.54%

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
1.45%
Glaukos Corporation stock logo
GKOS
Glaukos
5.90%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
7.40%
Liquidia Corporation stock logo
LQDA
Liquidia
25.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,000357.04 million351.87 millionOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
1,09458.73 million55.27 millionOptionable
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
49022.85 million21.16 millionOptionable
Liquidia Corporation stock logo
LQDA
Liquidia
5088.93 million66.16 millionOptionable

Recent News About These Companies

Is Liquidia Corporation (LQDA) A Good Stock To Buy Now?
Wall Street Zen Downgrades Liquidia (NASDAQ:LQDA) to Buy

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$16.53 -0.10 (-0.58%)
Closing price 03:59 PM Eastern
Extended Trading
$16.58 +0.05 (+0.28%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Glaukos stock logo

Glaukos NYSE:GKOS

$139.87 -2.32 (-1.63%)
Closing price 03:59 PM Eastern
Extended Trading
$139.72 -0.15 (-0.11%)
As of 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

LeMaitre Vascular stock logo

LeMaitre Vascular NASDAQ:LMAT

$95.96 -0.04 (-0.04%)
Closing price 03:59 PM Eastern
Extended Trading
$96.12 +0.16 (+0.17%)
As of 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Liquidia stock logo

Liquidia NASDAQ:LQDA

$79.73 +4.61 (+6.14%)
Closing price 04:00 PM Eastern
Extended Trading
$79.59 -0.14 (-0.18%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.